The relationship of antipsychotic medication class and adherence with treatment outcomes and costs for Florida Medicaid beneficiaries with schizophrenia.
about
Approaches to improve adherence to pharmacotherapy in patients with schizophreniaDoes assertive community treatment increase medication adherence for people with co-occurring psychotic and substance use disorders?Medication adherence and utilization in patients with schizophrenia or bipolar disorder receiving aripiprazole, quetiapine, or ziprasidone at hospital discharge: a retrospective cohort study.Psychotropic medication nonadherence among United States Latinos: a comprehensive literature review.How patient cost-sharing trends affect adherence and outcomes: a literature review.The Potential Role of Long-acting Injectable Antipsychotics in People with Schizophrenia and Comorbid Substance Use.Systematic review of the economic aspects of nonadherence to antipsychotic medication in patients with schizophreniaEffectiveness of sulpiride in adult patients with schizophrenia.Changes over time and disparities in schizophrenia treatment quality.Pharmacological treatment of schizophrenia with comorbid substance use disorder.Real-world adherence assessment of lurasidone and other oral atypical antipsychotics among patients with schizophrenia: an administrative claims analysis.Estimating the Impact of Adherence to and Persistence with Atypical Antipsychotic Therapy on Health Care Costs and Risk of Hospitalization.How to Improve Adherence to Medication and Follow-up in Chronic Mental Illnesses: Stakeholder Views.Economic impact of medication non-adherence by disease groups: a systematic review.The impact of non-adherence to medication in patients with schizophrenia on health, social care and societal costs. Analysis of the QUATRO study.
P2860
Q33645198-48576CEF-EA8F-4286-A5C9-1B8668FA0E74Q34182579-88CE4511-8622-4269-9B16-794D35C95005Q34362623-9131F89F-6507-4EE2-B5D4-10D49EDF4DC8Q35569720-569A0408-CDA3-4619-8A01-89105E0478C7Q35752951-4F5CACA5-D758-4781-AF54-ECCD387A6788Q36059843-9740AC40-D95D-4F5C-B9CB-8D338467BE68Q36755049-DA76AE63-2CE7-4933-A90B-EF5A40CBDACDQ36770037-4C001FD9-DEE9-4028-9A06-2000B966B320Q37463226-873286BD-2936-4B27-9319-10AEC0915DCBQ38658672-E07D34D6-7C42-4A38-8776-32E0B16C157FQ39015229-017C2D7D-D621-4C93-8B48-9C8B0F5FE54DQ40501293-5D62CD3D-5A5E-4AAA-A757-651E386A084BQ41017263-6103F2FE-5B37-4724-9F02-B025850A7D26Q47555825-FEDD3A43-A9C4-44FB-8E4F-E89E87182E15Q50714603-1A8CF479-EAE8-4603-AE81-BF26B0BBCF18
P2860
The relationship of antipsychotic medication class and adherence with treatment outcomes and costs for Florida Medicaid beneficiaries with schizophrenia.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
The relationship of antipsycho ...... eficiaries with schizophrenia.
@ast
The relationship of antipsycho ...... eficiaries with schizophrenia.
@en
The relationship of antipsycho ...... eficiaries with schizophrenia.
@nl
type
label
The relationship of antipsycho ...... eficiaries with schizophrenia.
@ast
The relationship of antipsycho ...... eficiaries with schizophrenia.
@en
The relationship of antipsycho ...... eficiaries with schizophrenia.
@nl
prefLabel
The relationship of antipsycho ...... eficiaries with schizophrenia.
@ast
The relationship of antipsycho ...... eficiaries with schizophrenia.
@en
The relationship of antipsycho ...... eficiaries with schizophrenia.
@nl
P2093
P2860
P1476
The relationship of antipsycho ...... eficiaries with schizophrenia.
@en
P2093
Ezra Ochshorn
M Scott Young
Marion A Becker
Ronald J Diamond
P2860
P2888
P304
P356
10.1007/S10488-006-0108-5
P577
2007-01-09T00:00:00Z
P5875
P6179
1009407342